The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Triplet vs quadruplet regimens for NDMM: selecting between these options
Shebli Atrash, MD, Levine Cancer Institute & Atrium Health, Charlotte, NC, discusses the comparison between triplet and quadruplet regimens in newly diagnosed multiple myeloma (NDMM). Dr Atrash highlights that quadruplet regimens, particularly those including anti-CD38 monoclonal antibodies, have consistently shown superior efficacy and encourages clinicians to utilize quadruplets over triplets. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
